Clinical implications of pharmacogenomics of statin treatment. In December the manufacturer said it had halted ads for the drug that the FDA criticized as misleading because they suggested Crestor is safer than has been proven. Each of these statins has a different effect on lipid profile. Crestor is used to lower the risk of stroke, heart attack, and certain other heart complications in men 50 years and older and women 60 years and older who have coronary heart disease or other risk factors. Eligibility was determined by medical history, physical examination, and clinical laboratory evaluation in a screening visit. For some patients, there may be pre-existing conditions or other personal factors that could cause a greater risk of developing muscle-related problems, including rhabdomyolysis, if they are using "statin" medications.

Statin type and dose did not significantly modify the association between Chinese ethnicity and other outcomes. This includes patients taking cyclosporine, Asian patients, and patients with severe renal insufficiency. A novel human hepatic organic anion transporting polypeptide OATP2. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. Take Crestor exactly as prescribed by your doctor. Patients We established a cohort of older adults i.

For incident diabetes outcome, we excluded matched sets of patients with evidence of baseline diabetes. Accessed August 6, When transporters were inhibited by intravenous rifampin, rosuvastatin AUC 0—48 and C max also showed no ethnic differences. To balance the benefits and risks of statins in patients, 2 facts should be emphasised: statins that have great benefits in decreasing cardiovascular and cerebrovascular events, and those best tolerated statins need to be identified. Available for Android and iOS devices. Keywords: clinical pharmacokinetics, drug interaction, race, organic anion-transporting polypeptide transporters, ABC transporters, efflux pumps, hepatic transport, intestinal absorption.

Initial dose: 5 mg once a day with or without food Maintenance dose: 5 mg to 20 mg once a day with or without food. Numerous genetic polymorphisms have been identified in the OATP-C gene and found to vary within and across ethnic groups. When we digitally quantified the data presented in Fig. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. Stop taking this medicine and tell your doctor right away if you become pregnant.